01 Apr, EOD - Indian

SENSEX 76024.51 (-1.80)

Nifty 50 23165.7 (-1.50)

Nifty Bank 50827.5 (-1.43)

Nifty IT 35980.65 (-2.45)

Nifty Midcap 100 51229.6 (-0.86)

Nifty Next 50 62372.1 (-1.06)

Nifty Pharma 20771.8 (-1.73)

Nifty Smallcap 100 15982.95 (-0.70)

01 Apr, EOD - Global

NIKKEI 225 35634.93 (0.03)

HANG SENG 23167.31 (-0.17)

S&P 5678.75 (-0.14)


Hot Pursuit News

You are Here : Home > News > Hot Pursuit News >

(31 Mar 2025, 13:58)

SPARC submits application for its ADC to US FDA to conduct global phase-1 study

Sun Pharma Advanced Research Company (SPARC) said that it has submitted an investigational new drug (IND) application with the US Food and Drug Administration (FDA) for its antibody–drug conjugate (ADC) SBO-154.


The IND application supports the next phase of development of SBO-154 which has completed the required IND-enabling preclinical studies with favorable results. A global phase-1 dose-escalation and expansion study has been planned to evaluate SBO-154 in treatment of solid tumors.

Antibody–drug conjugates or ADCs are a class of biopharmaceutical drugs designed as a targeted therapy for treating cancer. Unlike chemotherapy, ADCs are intended to target and kill tumor cells while sparing healthy cells.

SBO-154 is a novel humanized MUC1-SEA-targeted ADC developed by SPARC for the treatment of advanced solid tumours. SBO-154 specifically binds with high affinity to the SEA domain of MUC1, and functions by the release of the antimitotic payload after internalization and cleavage.

The released payload inhibits cell division and, thereby contributes to the shrinkage of tumours. SPARC had licensed anti-MUC1 antibody from Biomodifying a startup from the University of Tel Aviv.

Anil Raghavan, CEO of SPARC, said: "SBO-154, our first ADC is ready to advance in phase-1 with this IND submission, and this is an important milestone for SPARC as we hope to improve lives of cancer patients globally."

Sun Pharma Advanced Research Company (SPARC) is a pharmaceutical company focused on continuously improving standards of care for patients globally through innovation in therapeutics and delivery.

The scrip had declined 2.63% to end at Rs 148 on the BSE on Friday.


More News

Capital Market Publishers India Pvt. Ltd

401, Swastik Chambers, Sion Trombay Road, Chembur, Mumbai - 400 071, India.

Formed in 1986, Capital Market Publishers India Pvt Ltd pioneered corporate databases and stock market magazine in India. Today Capitaline corporate database cover more than 35,000 listed and unlisted Indian companies. Latest technologies and standards are constantly being adopted to keep the database user-friendly, comprehensive and up-to-date.

Over the years the scope of the databases has enlarged to cover economy, sectors, mutual funds, commodities and news. Many innovative online and offline applications of these databases have been developed to meet various common as well as customized requirements.

While all the leading institutional investors use Capitaline databases, Capital Market magazine gives access to the databases to individual investors through Corporate Scoreboard. Besides stock market and company-related articles, the magazine’s independent and insightful coverage includes mutual funds, taxation, commodities and personal finance.

The power of the database is harnessed by our fired-up reporters to generate interesting ideas. The reader-friendly presentation of the idea, supplemented by relevant data and information, can be accessed online through Capita Telefolio and Telefolio Gold. These ideas are used by individual investors as well as institutional investors to do further research and stay ahead.

Copyright @ Capital Market Publishers India Pvt.Ltd

Designed, Developed and maintained by CMOTS Infotech (ISO 9001:2015 Certified)

Site best viewed in Internet Explorer Edge ,   Google Chrome 115.0.5790.111 + ,   Mozilla Firefox 115.0.3 + ,   Opera 30.0+, Safari 16.4.1 +